Insurers won’t cover new Alzheimer’s treatment for some customers
Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients.
leqembi
Alzheimer’s drug now has full FDA approval, which means Medicare will pay for it
U.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease.
